Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
NCI-CCC Tumor Board Question
•
Cleveland Clinic
•
NCI-CCC Lymphoma Tumor Board Question
What is your preferred treatment for localized, stage I or contiguous stage II, grade IIIa follicular lymphoma?
Related Questions
How would you manage a frail patient with GCB DLBCL who is unable to complete R-CHOP but has moderate residual disease?
In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?
How would you manage a patient with a recent diagnosis of advanced DLBCL (non-GCB subtype) who has baseline grade 3 neuropathy?
What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?
How would you manage a patient w/ blastoid variant MCL given data w/ all the current BTKi regimens TRIANGLE, BOVEN, and TRAVERSE
How would you structure your monitoring for a low-risk leukemic TP53-negative mantle cell lymphoma with 5% MCL cells detected in both peripheral blood and bone marrow, mild splenomegaly, and no lymphadenopathy or B symptoms?
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
Does the recent publication of EPCORE FL-1 (Epcoritamab + R2) change your preferred 2L SOC for R/R FL?
How have the results of the SUNMO trial (mosunetuzumab + polatuzumab) impacted your treatment choices for Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma?
Do you still recommend consolidative allogeneic stem cell transplants for patients with Richter transformation in CR after frontline treatment in the modern era of therapies?
